Literature DB >> 24408925

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter.

David C Binder1, Hans Schreiber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24408925      PMCID： PMC3905982          DOI： 10.1158/0008-5472.CAN-13-2216

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  8 in total

1.  Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.

Authors:  David C Binder; Boris Engels; Ainhoa Arina; Ping Yu; James M Slauch; Yang-Xin Fu; Theodore Karrison; Byron Burnette; Christian Idel; Ming Zhao; Robert M Hoffman; David H Munn; Donald A Rowley; Hans Schreiber
Journal:  Cancer Immunol Res       Date:  2013-08       Impact factor: 11.151

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.

Authors:  Janis M Taube; Robert A Anders; Geoffrey D Young; Haiying Xu; Rajni Sharma; Tracee L McMiller; Shuming Chen; Alison P Klein; Drew M Pardoll; Suzanne L Topalian; Lieping Chen
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.

Authors:  Justin Kline; Ian E Brown; Yuan-Yuan Zha; Christian Blank; John Strickler; Harald Wouters; Long Zhang; Thomas F Gajewski
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

6.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

7.  Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

Authors:  Jaikumar Duraiswamy; Karen M Kaluza; Gordon J Freeman; George Coukos
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

8.  A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth.

Authors:  Frank T Wen; Ronald A Thisted; Donald A Rowley; Hans Schreiber
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110
  8 in total
  9 in total

Review 1.  Current position of TNF-α in melanomagenesis.

Authors:  Iuliana Nenu; Diana Tudor; Adriana Gabriela Filip; Ioana Baldea
Journal:  Tumour Biol       Date:  2015-08-18

2.  Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.

Authors:  Ainhoa Arina; Theodore Karrison; Eva Galka; Karin Schreiber; Ralph R Weichselbaum; Hans Schreiber
Journal:  Cancer Immunol Res       Date:  2017-01-11       Impact factor: 11.151

3.  Roles of PD-1, Tim-3 and CTLA-4 in immunoregulation in regulatory T cells among patients with sepsis.

Authors:  Dong-Na Gao; Zhi-Xiang Yang; Qing-Hui Qi
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 4.  Immunotherapy for cancer in the central nervous system: Current and future directions.

Authors:  David C Binder; Andrew A Davis; Derek A Wainwright
Journal:  Oncoimmunology       Date:  2015-09-11       Impact factor: 8.110

5.  Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.

Authors:  Azharuddin Sajid Syed Khaja; Salman M Toor; Haytham El Salhat; Issam Faour; Navid Ul Haq; Bassam R Ali; Eyad Elkord
Journal:  Oncotarget       Date:  2017-05-16

6.  Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery.

Authors:  Ramya Sivakumar; Marina Chan; Jiye Stella Shin; Nao Nishida-Aoki; Heidi L Kenerson; Olivier Elemento; Himisha Beltran; Raymond Yeung; Taranjit S Gujral
Journal:  Oncoimmunology       Date:  2019-10-10       Impact factor: 8.110

7.  T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors.

Authors:  Takayoshi Yamauchi; Toshifumi Hoki; Takaaki Oba; Vaibhav Jain; Hongbin Chen; Kristopher Attwood; Sebastiano Battaglia; Saby George; Gurkamal Chatta; Igor Puzanov; Carl Morrison; Kunle Odunsi; Brahm H Segal; Grace K Dy; Marc S Ernstoff; Fumito Ito
Journal:  Nat Commun       Date:  2021-03-03       Impact factor: 14.919

Review 8.  Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment.

Authors:  Jianyun Jiang; Hongmei Ying
Journal:  J Exp Clin Cancer Res       Date:  2022-08-13

9.  Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.

Authors:  Derek A Wainwright; Alan L Chang; Mahua Dey; Irina V Balyasnikova; Chung Kwon Kim; Alex Tobias; Yu Cheng; Julius W Kim; Jian Qiao; Lingjiao Zhang; Yu Han; Maciej S Lesniak
Journal:  Clin Cancer Res       Date:  2014-04-01       Impact factor: 12.531
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.